MECHANISM OF ACTION
CD38 is a glycoprotein found on the surface of various blood cells. It is weakly expressed on lymphoid and myeloid cells, but highly expressed on myeloma cells. 1 Daratumumab is a human monoclonal antibody that targets CD38. Daratumumab is a human monoclonal antibody that targets CD38 and induces antibody-dependent cellular toxicity and complement-dependent cytotoxicity in myeloma cells. 1, 2 Antibody-dependent cellular phagocytosis of tumor cells 3 and induction of apoptosis 2 have also been described as possible mechanisms of daratumumab's action.
PHARMACOKINETICS
Following an infusion of 16 mg/kg, the mean maximum serum concentration (C max ) is 915 mcg/mL. With a dosing regimen weekly for 8 weeks, then every 2 weeks for 16 weeks, the steady state serum concentration is reached at about 5 months. The mean clearance and volume of distribution (V d ) were 171.4 mL/day and 4.7 L, respectively. 4 Disposition of daratumumab is both concentration-and dose-dependent, with lower clearance at higher concentrations. 5 Selected therapeutic regimens of daratumumab appear in Table 1 
TOXICITIES
Most of the toxicities listed below are presented according to their degree of severity. Higher grades represent more severe toxicities. Although there are several grading systems for cancer chemotherapy toxicities, all are similar. One of the frequently used systems is the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (http:// evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf).
Oncologists generally do not adjust doses or change therapy for grade 1 or 2 toxicities; but make, or consider, dosage reductions or therapy changes for grade 3 or 4 toxicities. Incidence values are rounded to the nearest whole percent unless incidence was less than or equal to 0.5%. A. Cardiovascular: Atrial fibrillation (grade 3 or 4) 3% 8 ; flushing (grade 1 or 2) 6% 8 ; hypertension 10%, 10 (grade 1 or 2) 6%, 8 (grade 3 or 4) 5% 10 ; hypotension (grade 1 or 2) 6% 8 ; palpitations (grade 1 or 2) 3% 8 ; peripheral edema 10%, 10 (grade 3 or 4) 1% 10 ; tachycardia (grade 1 or 2) 6%. 8 
MECHANISM OF ACTION
Osimertinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that irreversibly binds to both the activating EGFR and the EGFR T790M resistance mutation. 14
PHARMACOKINETICS
AZD9291 has a median time to time to maximum serum concentration (T max ) of 6 hours 15, 16 and a mean half-life of 55 hours. 15 Steady state concentration is reached in 22 days. Following 80 mg/day, the mean AUC tau is 12,120 nM•h on day 22; and the mean maximum serum concentration (C max ) is 635.4 nM. The AUC of the metabolites AZ5104 and AZ7550 is approximately 10% of the AUC of the parent drug. 15 With daily dosing, the time to steady state concentration is 15 days. Osimetrinib is highly bound to serum protein, and has a mean volume of distribution (V d ) of 986 L. The drug is metabolized by oxidation by the CYP3A and dealkylation in the liver to 2 active metabolites: AZ5104 and AZ7550. Osimertinib has a mean half-life (T ½ ) of 48 hours and an oral clearance of 14.2 L/h. Osimertinib is excreted primarily in the feces (68%), with about 14% excreted in the urine. About 2% of the drug is excreted unchanged. 16 Selected therapeutic regimens of osimertinib appear in Table 2 a. Mix the tablet in approximately 50 mL of non-carbonated water and stir until it is completely dispersed. b. Drink the mixture or administer through a feeding tube; rinse the container with 4 to 8 ounces of water and drink or administer through a feeding tube.
TOXICITIES
Most of the toxicities listed below are presented according to their degree of severity. Higher grades represent more severe toxicities. Although there are several grading systems for cancer chemotherapy toxicities, all are similar. One of the frequently used systems is the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (http://evs. nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf). Oncologists generally do not adjust doses or change therapy for grade 1 or 2 toxicities; but make, or consider, dosage reductions or therapy changes for grade 3 or 4 toxicities. Incidence values are rounded to the nearest whole percent unless incidence was less than or equal to 0.5%. 15 (grade 3 to 5) 1%. 15
DOSE ADJUSTMENT
A. Hepatic 16 : 1. Mild impairment: a. Bilirubin less than the ULN and AST less than or equal to 1.5 times the ULN, no adjustment required. b. Bilirubin greater than 1.5 times the ULN and any AST, no adjustment required. 2. Moderate or severe impairment, no information available. B. Renal 16 :
1. Creatinine clearance (Cl cr ) greater than or equal to 60 mL/min and less than or equal to 89 mL/min, no adjustment required. 2. Cl cr greater than or equal to 30 mL/min and less than or equal to 9 mL/min, no adjustment required. 3. Cl cr less than 30 mL/min, no information available. Note: PO = oral. a Conforms to dosing information listed in the manufacturer's labeling
